This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay D is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
In a quiet office in an industrial park in Jerusalem, an Israeli woman in a white coat slowly binds a black coil to the surface of a metal dome. She is creating the insides of a helmet that may help treat millions of people with clinical depression.
The machine is made by Brainsway®, a Tel Aviv-listed medical devices company, which has a market capitalisation of about US$260 million (S$355 million). It has pioneered a treatment known as “deep transcranial magnetic stimulation”, using a helmet to aim magnetic fields at a patient’s brain tissues. This can target the reward system in the brain, helping to counter and relieve symptoms of depression.
Read more here.